Quest Diagnostics Inc. (DGX) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic path...
Quest Diagnostics Inc.'s revenue increased 11.8% year over year, from $9.87B to $11.04B.
Net income increased 13.9% over the same period, from $871.0M to $992.0M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 47% in total.
Total debt decreased by 8.0% to $5.17B.
The debt-to-equity ratio stands at 0.72, indicating a moderate leverage profile.
Operating cash flow grew 41.4% to $1.89B.
Quest Diagnostics Inc. maintains a moderate net profit margin of 9.0%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $6.96B+49.2% | $662.0M | $2.32B | $995.0M | $745.0M | $13.48B | $3.95B | $6.42B |
| Q1 FY2024 | $2.37B-66.0% | $194.0M | $771.0M | $300.0M | $154.0M | $13.95B | $3.80B | $6.43B |
| Q2 FY2024 | $4.76B+101.3% | $423.0M | $1.57B | $655.0M | $514.0M | $13.88B | $3.82B | $6.62B |
| Q3 FY2024 | $7.25B+52.2% | $649.0M | $2.39B | $985.0M | $870.0M | $16.09B | $5.65B | $6.81B |
| Q1 FY2025 | $2.65B-63.4% | $220.0M | $863.0M | $346.0M | $314.0M | $15.80B | $5.86B | $6.93B |
| Q2 FY2025 | $5.41B+104.1% | $502.0M | $1.81B | $784.0M | $858.0M | $15.97B | $5.17B | $7.23B |
| Q3 FY2025 | $8.23B+52.0% | $747.0M | $2.75B | $1.17B | $1.42B | $16.20B | $5.17B | $7.26B |
| Q1 FY2026 | $2.90B-64.8% | $252.0M | $942.0M | $399.0M | $278.0M | $16.67B | $5.16B | $7.37B |
Balance Sheet Summary (Latest Period)
Total Assets
$16.23B
Total Liabilities
$9.05B
Total Equity
$7.17B
Cash & Equivalents
$420.0M
Total Debt
$5.17B
Current Assets
$2.38B
Current Liabilities
$2.28B
Retained Earnings
$9.99B